COVID-19 Treatment Study for Non-Hospitalized Participants

Clinical Trial Title

A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19 (SCORPIO-HR)

National Clinical Trial Number:


Contact Information

Rush Infectious Diseases

Clinical Trial Protocol Description:

A5407 is a phase 3, multicenter, randomized, double-blind, placebo-controlled study measuring the clinical and antiviral effects of an oral medication in non-hospitalized participants with Covid-19. The study lasts 24 weeks and participants must be 18 years or older to participate. Study drug (or placebo) is taken for 5 consecutive days by mouth. Required activities from participants include completing symptom diaries and providing blood samples and both nasopharyngeal and anterior nasal swabs.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Are 18 years of age or older.
  • Have an active COVID-19 infection.

You will be excluded from the study if any of the following criteria apply to you:

  • Are breastfeeding or pregnant.
  • Are on dialysis or have a history of liver cirrhosis.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Study Details

Clinical Trial Investigator

Mariam Aziz, MD

Contact Information

Rush Infectious Diseases

Clinical Trial Location

RUSH University Medical Center


RUSH University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more